å±±èïŒã¯ã€ã«ãã€ã ïŒã¯ã倿¥ãããæ°éçæ³ã§PMSïŒPremenstrual Syndromeãæçµåçå矀ïŒã®ç·©åã«å©çšãããŠããŸããããããŠãå±±èã®ïŒã€ããã²ãã³ãã®ç²æ«ã§ããèšåºè©Šéšã宿œãããPMSã«å¯ŸããŠæå¹æ§ã瀺ãããŠããŸããã
ãŸãããã®å ±åã玹ä»ã§ãã
ãã²ãã³ãã¯ããžãªã¹ã²ãã³ãé ç³äœãšããŠå€ãå«ãŸããŠããå±±èã§ããããšç¥ãããŠããããã²ãã³ãç²æ«ã®ãžãªã¹ã²ãã³å«æéã¯255mg/100gãšããå ±åããããŸãã®ã§ãäžèšããèšåºè©Šéšã®æåé300mgã«ããããžãªã¹ã²ãã³å«æéã¯0.765mgã«ãªããŸãã
ããå°éã§æå¹æ§ã瀺ãããŠãããŸãã
è¬åŠéšã®å çæ¹æ°ããã¹ããã€ãéªšæ Œãæã£ãŠããããã ãããšã®ããšã
ãžãªã¹ã²ãã³ã¯ãæ²¹ã«æžæ¿ãããå æ¥ããªããšåžåããã«ããæåã§ãã®ã§ããœããã«ãã»ã«ä»¥å€ã®å€åã«ãããªããå人çã«ããžãªã¹ã²ãã³å æ¥äœåæãæ¡çšããããšããªã¹ã¹ã¡ããŠãããŸãã
é åéãšããŠã¯ããžãªã¹ã²ãã³ãšããŠ8mg/æ¥ä»¥äžïŒåŒç€Ÿãžãªã¹ã²ãã³å æ¥äœåæã§45mg/æ¥ä»¥äžïŒã®æåããªã¹ã¹ã¡ã§ãã
ãã®å ±åã®åæãèªã¿ãŸããããçæ³è«ãèšããšãããå°ãæçµåšæãã³ã³ãããŒã«ããŠãVASãæ¡è¡ã®ã¿ã€ãã³ã°ãªã©ãäžå®åããæ¹ãè¯ããšæããŸããã
ç§ã¯ããŸãéã®ããèšåºè©Šéšã§ããã®éšåããã®åãèŠåŽããã®ã§ã»ã»ã»ã
ã¡ãªã¿ã«ãåŒç€Ÿã®ãžãªã¹ã²ãã³åæãçšããŠãåæ§ãªæå¹æ§è©äŸ¡è©Šéšãè¡ãããšã¯ãæ©èœæ§è¡šç€ºé£å察å¿ãã«ããç¹ãªã©ãããããªèгç¹ããããªããªãããŒãã«ãé«ãã§ãã
ãããšããŠãããžãªã¹ã²ãã³å æ¥äœã ããã
äœãã«ããŠãããšãŠãåèã«ãªãå ±åã§ãããç¹ã«ãè©äŸ¡ç³»ã®éšåã
ãã®é åã¯ããã§ã ããã¯åéã§ããæçµã«ããè²§è¡åæ§ãéåžžã«éèŠãªåéã ãšæããŸããæ¯éããã®æç®ã掻çšããŠPMSç³»ãµããªã«é åããŠãããã°ãšäŒãã§ãããŸãã
ãªããå人çãªèŠè§£ã§ããããã¢ã°ããã³å€ã®äœäžã«ããäžæçãªéæ¬ ä¹çç¶ãPMSçç¶ã®æ§æèŠçŽ ã ãšèããŠããŸãããªã®ã§ãè¯è³ªãªéããã£ããé åããããšãæãŸãããšèããŠããŸãã
P.S.
ã«ãã»ã«ã§æåãšãªã£ãŠããŸãããããŒãã«ãã»ã«ãªã®ãïŒãœããã«ãã»ã«ãªã®ãïŒãšããç¹ããšãŠãæ°ã«ãªããŸãã
ãã®äž¡å€åã«ãã£ãŠãå šãçµæãéã£ãŠããå¯èœæ§ãããã®ã§ã
ãŸãããã®å ±åã玹ä»ã§ãã
The effect of Dioscorea esculenta powder on prostaglandin E2 and cytochrome c oxidase subunit 2 levels, menstrual pain, and premenstrual syndrome in young women: A randomized double-blind controlled trial
Abstract
Background Diosgenin, extracted from Dioscorea esculenta, has been reported to decrease prostaglandin E2 (PGE2) levels and any other inflammatory cytokine in rodents. However, it is still unclear whether D. esculenta intake suppressed PGE2 production and menstrual pain and premenstrual syndrome (PMS) in younger female. Aim This study aims to investigate the effect of D. esculenta intake on PGE2 and cytochrome c oxidase subunit 2 (COX-2) levels and on menstrual pain and PMS in young women. This is a randomized, double-blind, placebo-controlled, crossover study. Methods Ten healthy young females were administered either a placebo or D. esculenta (300 mg/day) for 4 weeks, followed by a 4-week washout period. Fasting blood sample was taken from the fingertips on the second day of menstrual cycle began and obtained 24h before the last D. esculenta to avoid acute effects. Participants then switched treatments for 4 weeks as a second trial. Plasma PGE2 and COX-2 levels were measured before and after each trial. The visual analogue scale (VAS), McGill pain questionnaire (MPQ), and Daily Record of Severity of Problems (DRSP) were also evaluated. The study was set and conducted from 2019 to 2020. Results PGE2 and COX-2 levels significantly decreased after D. esculenta intake compared to placebo (p = 0.038, p = 0.042 each). The VAS and DRSP scores were also significantly lower after D. esculenta intake (p = 0.046, p = 0.035 each).
Conclusion Four-week D. esculenta intake suppressed PGE2 and COX-2 levels resulting in an improvement in PMS symptoms and menstrual pain in young women.
Nutr Health. 2022;2601060221130889.
ããâãGoogle翻蚳
è¥ã女æ§ã®ããã¹ã¿ã°ã©ã³ãžã³ E2 ããã³ããã¯ãã C ãªãã·ããŒãŒ ãµããŠããã 2 ã¬ãã«ãæçµçãããã³æçµåçå矀ã«å¯ŸããDioscorea esculentaïŒãã²ãã³ãïŒç²æ«ã®å¹æ: ã©ã³ãã åäºéç²æ€æ¯èŒè©Šéš
èŠæš
èæ¯ Dioscorea esculenta ããæœåºããããžãªã¹ã²ãã³ã¯ããã£æ¯é¡ã®ããã¹ã¿ã°ã©ã³ãžã³ E2 (PGE2) ã¬ãã«ããã³ãã®ä»ã®ççæ§ãµã€ãã«ã€ã³ãäœäžãããããšãå ±åãããŠããŸãã ããããD. esculenta ã®æåãè¥ã女æ§ã® PGE2 ç£çãšæçµçããã³æçµåçå矀 (PMS) ãæå¶ãããã©ããã¯ãŸã äžæã§ãã ç®ç ãã®ç ç©¶ã¯ãè¥ã女æ§ã® PGE2 ããã³ããã¯ãã c ãªãã·ããŒãŒ ãµããŠããã 2 (COX-2) ã¬ãã«ãããã³æçµçããã³ PMS ã«å¯Ÿãã D. esculenta æåã®åœ±é¿ã調æ»ããããšãç®çãšããŠããŸãã ããã¯ãã©ã³ãã åãäºéç²æ€ããã©ã»ãå¯Ÿç §ãã¯ãã¹ãªãŒããŒç ç©¶ã§ããæ¹æ³ 10 人ã®å¥åº·ãªè¥ã女æ§ã«ãã©ã»ããŸã㯠D. esculenta (300 mg/æ¥) ã 4 é±éæäžãããã®åŸ 4 é±éã®äŒè¬æéãèšããŸããã ç©ºè ¹æè¡æ¶²ãµã³ãã«ã¯ãæ¥æ§åœ±é¿ãé¿ããããã«ãæçµåšæéå§ã® 2 æ¥ç®ã«æå ããæ¡åãããæåŸã® D. esculenta ã® 24 æéåã«æ¡åãããŸããã ãã®åŸãåå è 㯠2 åç®ã®è©Šéšãšã㊠4 é±éæ²»çãåãæ¿ããŸããã å詊éšã®ååŸã«ãè¡æŒ¿ PGE2 ããã³ COX-2 ã¬ãã«ã枬å®ããŸããã ããžã¥ã¢ã« ã¢ããã° ã¹ã±ãŒã« (VAS)ããã®ã«çŒçã¢ã³ã±ãŒã (MPQ)ãåé¡ã®éçåºŠã®æ¥æ¬¡èšé² (DRSP) ãè©äŸ¡ãããŸããã ãã®ç ç©¶ã¯2019幎ãã2020幎ã«èšå®ãã宿œãããŸãããçµæ PGE2ããã³COX-2ã¬ãã«ã¯ããã©ã»ããšæ¯èŒããŠD. esculentaæååŸã«ææã«æžå°ããŸããïŒããããp = 0.038ãp = 0.042ïŒã VAS ããã³ DRSP ã¹ã³ã¢ã D. esculenta æååŸã«ææã«äœäžããŸãã (ãããã p = 0.046ãp = 0.035)ã çµè« 4 é±éã® D. esculenta æåã«ãã PGE2 ããã³ COX-2 ã¬ãã«ãæå¶ãããè¥ã女æ§ã® PMS çç¶ãšæçµçãæ¹åãããŸããã
ãã²ãã³ãã¯ããžãªã¹ã²ãã³ãé ç³äœãšããŠå€ãå«ãŸããŠããå±±èã§ããããšç¥ãããŠããããã²ãã³ãç²æ«ã®ãžãªã¹ã²ãã³å«æéã¯255mg/100gãšããå ±åããããŸãã®ã§ãäžèšããèšåºè©Šéšã®æåé300mgã«ããããžãªã¹ã²ãã³å«æéã¯0.765mgã«ãªããŸãã
ããå°éã§æå¹æ§ã瀺ãããŠãããŸãã
è¬åŠéšã®å çæ¹æ°ããã¹ããã€ãéªšæ Œãæã£ãŠããããã ãããšã®ããšã
ãžãªã¹ã²ãã³ã¯ãæ²¹ã«æžæ¿ãããå æ¥ããªããšåžåããã«ããæåã§ãã®ã§ããœããã«ãã»ã«ä»¥å€ã®å€åã«ãããªããå人çã«ããžãªã¹ã²ãã³å æ¥äœåæãæ¡çšããããšããªã¹ã¹ã¡ããŠãããŸãã
é åéãšããŠã¯ããžãªã¹ã²ãã³ãšããŠ8mg/æ¥ä»¥äžïŒåŒç€Ÿãžãªã¹ã²ãã³å æ¥äœåæã§45mg/æ¥ä»¥äžïŒã®æåããªã¹ã¹ã¡ã§ãã
ãã®å ±åã®åæãèªã¿ãŸããããçæ³è«ãèšããšãããå°ãæçµåšæãã³ã³ãããŒã«ããŠãVASãæ¡è¡ã®ã¿ã€ãã³ã°ãªã©ãäžå®åããæ¹ãè¯ããšæããŸããã
ç§ã¯ããŸãéã®ããèšåºè©Šéšã§ããã®éšåããã®åãèŠåŽããã®ã§ã»ã»ã»ã
ã¡ãªã¿ã«ãåŒç€Ÿã®ãžãªã¹ã²ãã³åæãçšããŠãåæ§ãªæå¹æ§è©äŸ¡è©Šéšãè¡ãããšã¯ãæ©èœæ§è¡šç€ºé£å察å¿ãã«ããç¹ãªã©ãããããªèгç¹ããããªããªãããŒãã«ãé«ãã§ãã
ãããšããŠãããžãªã¹ã²ãã³å æ¥äœã ããã
äœãã«ããŠãããšãŠãåèã«ãªãå ±åã§ãããç¹ã«ãè©äŸ¡ç³»ã®éšåã
ãã®é åã¯ããã§ã ããã¯åéã§ããæçµã«ããè²§è¡åæ§ãéåžžã«éèŠãªåéã ãšæããŸããæ¯éããã®æç®ã掻çšããŠPMSç³»ãµããªã«é åããŠãããã°ãšäŒãã§ãããŸãã
ãªããå人çãªèŠè§£ã§ããããã¢ã°ããã³å€ã®äœäžã«ããäžæçãªéæ¬ ä¹çç¶ãPMSçç¶ã®æ§æèŠçŽ ã ãšèããŠããŸãããªã®ã§ãè¯è³ªãªéããã£ããé åããããšãæãŸãããšèããŠããŸãã
P.S.
ã«ãã»ã«ã§æåãšãªã£ãŠããŸãããããŒãã«ãã»ã«ãªã®ãïŒãœããã«ãã»ã«ãªã®ãïŒãšããç¹ããšãŠãæ°ã«ãªããŸãã
ãã®äž¡å€åã«ãã£ãŠãå šãçµæãéã£ãŠããå¯èœæ§ãããã®ã§ã
ã远èšã
ãã²ãã³ãã®ç ç©¶ã¯ã以åã«ã玹ä»ããŸããã
äžæ¹ãæ©èœæ§é¢äžæåãæç¢ºã«ãããããèšåºè©Šéšãè¡ããç¶ããŠãããæ©èœæ§è¡šç€ºé£åãžã®å¯Ÿå¿ãæèããŠããªãã
ãšãŠãå¿äœãªãã
ã§ãããžãªã¹ã²ãã³ãæ©èœæ§é¢äžæåãšãããšãä»ã®å±±èçŽ æïŒä»£è¡šäŸã¯åŒç€Ÿã®ãžãªãã¯ãŒïŒïŒïŒã«ãå©çšãããŠããŸããæµããªãããšãçè§£ããŠããã®ã ããã
åŒç€Ÿããžãªã¹ã²ãã³CDã§ããããèšåºè©Šéšãèšç»ããŠããªãç¹ãšåãçç±ã§ãã
ãã²ãã³ãã«é¢ããŠãçæ³ã¯ãè€æ°ååšãããžãªã¹ã²ãã³é ç³äœã®å«æéã®æ¯çïŒãã²ãã³ãç¹æã®æ¯çïŒãæ±ãããžãªã¹ã²ãã³éé¢äœå«æéããé ç³äœå«æéãèšç®å€ã§æ±ãããã²ãã³ãç±æ¥ãžãªã¹ã²ãã³é ç³äœã®å®éæ¹æ³ã確ç«ããããšã ãšæããŸãã
ã¡ãã£ãšæéããããã®ã¯ãæ¯çãæç¢ºã«ããããšã§ãããæç¢ºã«ãªã£ããè«æçºè¡šãããããåŒçšããŠäžèšã®ããã«å®éåæãè¡ãã°ãããšæããŸãã
ã¡ãªã¿ã«ããžãªãã¯ãŒïŒïŒã«äœ¿çšãããŠããæå±±èã¯ãæ¯çãŸã§ç®åºãããŠããŸããããæ§é è§£æãŸã§è¡ãããŠããŸãã
ãã²ãã³ãã®ç ç©¶ã¯ã以åã«ã玹ä»ããŸããã
äžæ¹ãæ©èœæ§é¢äžæåãæç¢ºã«ãããããèšåºè©Šéšãè¡ããç¶ããŠãããæ©èœæ§è¡šç€ºé£åãžã®å¯Ÿå¿ãæèããŠããªãã
ãšãŠãå¿äœãªãã
ã§ãããžãªã¹ã²ãã³ãæ©èœæ§é¢äžæåãšãããšãä»ã®å±±èçŽ æïŒä»£è¡šäŸã¯åŒç€Ÿã®ãžãªãã¯ãŒïŒïŒïŒã«ãå©çšãããŠããŸããæµããªãããšãçè§£ããŠããã®ã ããã
åŒç€Ÿããžãªã¹ã²ãã³CDã§ããããèšåºè©Šéšãèšç»ããŠããªãç¹ãšåãçç±ã§ãã
ãã²ãã³ãã«é¢ããŠãçæ³ã¯ãè€æ°ååšãããžãªã¹ã²ãã³é ç³äœã®å«æéã®æ¯çïŒãã²ãã³ãç¹æã®æ¯çïŒãæ±ãããžãªã¹ã²ãã³éé¢äœå«æéããé ç³äœå«æéãèšç®å€ã§æ±ãããã²ãã³ãç±æ¥ãžãªã¹ã²ãã³é ç³äœã®å®éæ¹æ³ã確ç«ããããšã ãšæããŸãã
ã¡ãã£ãšæéããããã®ã¯ãæ¯çãæç¢ºã«ããããšã§ãããæç¢ºã«ãªã£ããè«æçºè¡šãããããåŒçšããŠäžèšã®ããã«å®éåæãè¡ãã°ãããšæããŸãã
ã¡ãªã¿ã«ããžãªãã¯ãŒïŒïŒã«äœ¿çšãããŠããæå±±èã¯ãæ¯çãŸã§ç®åºãããŠããŸããããæ§é è§£æãŸã§è¡ãããŠããŸãã
- ã«ããŽãªïŒ
- ææ°ç ç©¶ããŒã¿
- ãã§ã ããã¯












ãã®ããã°ã«ã³ã¡ã³ãããã«ã¯ãã°ã€ã³ãå¿ èŠã§ãã
ãããã°ã¢ãŠã
ãã®èšäºã«ã¯èš±å¯ãŠãŒã¶ããã³ã¡ã³ããã§ããŸããã